Ahmed Sadek, Farag Michael M, Attia Heba, Balkhi Bander, Adel Islam M, Nemr Asmaa Ashraf
Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Cairo University, Cairo 11562, Egypt.
Department of Microbiology and Immunology, Faculty of Pharmacy, Cairo University, Cairo 11562, Egypt.
Int J Pharm X. 2025 Feb 24;9:100322. doi: 10.1016/j.ijpx.2025.100322. eCollection 2025 Jun.
This work aimed to prepare Terconazole loaded proniosomes (TCZ-PNS) utilizing modified coacervation technique for the management of fungal keratitis. Terconazole (TCZ) is a potent antifungal with poor aqueous solubility posing intricacies in its incorporation in ocular formulations. A 2 factorial design was adopted to probe independent formulation variables including A: Lecithin: cholesterol ratio, B: Surfactant: cholesterol ratio and C: Span® 80 contribution (% of total SAA). The formulae, generated by the design, were prepared and scrutinized regarding entrapment efficiency (%EE), particle size (PS), polydispersity index (PDI) and zeta potential (ZP). Numerical desirability algorithms selected an optimum TCZ-PNS which boasted plausible %EE (89.51 % ± 0.94 %), nanoscale vesicles consistent with TEM measurements (247.9 ± 0.42 nm), a sufficiently high ZP (-43.42 ± 0.85 mV), and an in-vitro biphasic release profile that remained stable even after Gamma irradiation and short-term storage. The transcorneal ex-vivo permeation of TCZ-PNS was higher than that of TCZ suspension (≈ 2-fold). The formulation was further evaluated for pH, corneal hydration threshold, and histopathological safety, confirming its suitability for ocular application. Confocal laser microscopy revealed substantial corneal uptake (approximately twice as deep as of TCZ suspension). Additionally, microbiological assessments of the optimal TCZ-PNS compared to TCZ suspension demonstrated an inhibition zone nearly 50 % larger, a significantly lower MIC and MFC (64-fold reduction), and enhanced biofilm inhibition activity across most tested concentrations. These findings suggest that TCZ-PNS could be a propitious treatment choice to deeply deliver antifungal therapy for the eradication of deeply rooted and inaccessible fungal keratitis.
本研究旨在利用改良凝聚技术制备载有特康唑的前体脂质体(TCZ - PNS),用于治疗真菌性角膜炎。特康唑(TCZ)是一种强效抗真菌药,但其水溶性差,给将其纳入眼用制剂带来了复杂性。采用二因素设计来探究独立的制剂变量,包括A:卵磷脂与胆固醇比例、B:表面活性剂与胆固醇比例以及C:司盘®80的用量(占总表面活性剂的百分比)。根据该设计生成的配方制备并考察了包封率(%EE)、粒径(PS)、多分散指数(PDI)和zeta电位(ZP)。数值合意性算法选择了一种最佳的TCZ - PNS,其具有合理的%EE(89.51%±0.94%)、与透射电镜测量结果一致的纳米级囊泡(247.9±0.42nm)、足够高的ZP(-43.42±0.85mV)以及即使在伽马射线辐照和短期储存后仍保持稳定的体外双相释放曲线。TCZ - PNS的角膜离体渗透高于TCZ混悬液(约2倍)。进一步评估了该制剂的pH值、角膜水化阈值和组织病理学安全性,证实其适用于眼部应用。共聚焦激光显微镜显示角膜摄取量显著增加(约为TCZ混悬液的两倍深)。此外,与TCZ混悬液相比,对最佳TCZ - PNS进行的微生物学评估显示抑菌圈几乎大50%,最低抑菌浓度(MIC)和最低杀菌浓度(MFC)显著降低(降低64倍),并且在大多数测试浓度下生物膜抑制活性增强。这些发现表明,TCZ - PNS可能是一种有利的治疗选择,可深入递送抗真菌疗法,以根除根深蒂固且难以触及的真菌性角膜炎。